H3 Biomedicine

Graphic image of a graveyard with tombstones a full moon and a raven perched on a branch

The 2022 Biotech Graveyard

Biotech's tumbling market has proven especially perilous, and, for many companies, clinical disappointments were followed by financial dead ends and closures.

Max Bayer Nov 21, 2022 3:00am

SCOOP: Eisai closing oncology R&D wing H3 Biomedicine

Jul 18, 2022 11:43am

Eisai unit H3 Biomedicine poaches Kura Oncology founder as CMO

Feb 20, 2020 7:55am

Bristol-Myers, H3 Biomedicine explore RNA splicing drugs for cancer

Dec 17, 2018 9:51am

RNA splicing mutations occur in more cancers than we thought

Apr 3, 2018 3:28pm

Chutes & Ladders—Celgene poaches top Merck R&D exec Plenge

May 4, 2017 4:02pm